Laura Crotty Alexander, MD, ATSF, outlines her presentation on e-cigarette or vaping product use-associated lung injury (EVALI) and other vaping diseases in the time of COVID-19 and beyond.
Laura Crotty Alexander, an associate professor of medicine at the University of California, San Diego, previews her talk "EVALI and Other Vaping Diseases in the Time of COVID and Beyond," to be presented at this year's American Thoracic Society (ATS) meeting. Crotty Alexander is also the section chief of pulmonary critical care at the Veterans Affairs San Diego Healthcare System.
Transcript:
Can you introduce yourself and give a preview of your talk "EVALI and Other Vaping Diseases in the Time of COVID and Beyond?"
I'm Laura Crotty Alexander. I'm an associate professor of medicine at the University of California, San Diego. I'm the section chief of pulmonary critical care at the VA San Diego Healthcare System.
I've been working in the field of e-cigarettes for over 8 years, so I got very interested in the e-cigarette or vaping associated lung injury epidemic, also called EVALI, that began in 2019, and is ongoing.
We have an entire symposium dedicated to EVALI and my talk, in particular, dives into some of the interesting facets of this epidemic that began in 2019 and is ongoing, and how to really separate it out from all the other vaping-associated health effects and lung effects in particular, that we've seen over the past decade. I'll be talking about different chemicals that are responsible for EVALI, in particular, and other lung diseases that are caused by vaping.
What are you most looking forward to at ATS 2021?
I would say that I'm looking forward to "seeing" people that I usually only see at the ATS every year, I'm still looking forward to that. It'll be good to see faces via Zoom and chatting via text and interacting with a lot of people through DocMatter. I think it'll be more social than at least last year, so it'll be a step in the right direction.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More